CSIMarket
 
Castle Biosciences Inc   (CSTL)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $18.8500 $-0.45 -2.332%
Day's High: $19.36 Week Perf: -5.99 %
Day's Low: $ 18.68 30 Day Perf: -19.79 %
Volume (M): 308 52 Wk High: $ 26.70
Volume (M$): $ 5,808 52 Wk Avg: $19.35
Open: $19.13 52 Wk Low: $11.66



 Market Capitalization (Millions $) 506
 Shares Outstanding (Millions) 27
 Employees 200
 Revenues (TTM) (Millions $) 220
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) -24
 Capital Exp. (TTM) (Millions $) 14

Castle Biosciences Inc
Castle Biosciences Inc is a medical technology company that specializes in molecular diagnostics for skin cancer. The company is based in Friendswood, Texas, and was founded in 2008 by Derek Maetzold, James Patterson and Federico Monsonego.

Castle Biosciencese mission is to improve patientse lives through the development of highly accurate and clinically actionable diagnostics for challenging cancer types. The company focuses on developing and commercializing genomic-based diagnostic tests that provide physicians and patients with accurate information to help identify the most effective treatment options.

The companyes flagship diagnostic test is DecisionDxe-Melanoma, a gene expression profile test that provides an individualized risk assessment for patients with cutaneous melanoma. The test is designed to help physicians determine which patients are at high risk of recurrence and who would benefit from closer surveillance and more aggressive treatment.

In addition to DecisionDxe-Melanoma, Castle Biosciences has developed diagnostic tests for uveal melanoma, cutaneous squamous cell carcinoma, and other cancers. The company also offers a suite of testing services for physicians, including gene expression profiling, next-generation sequencing, and pathology services.

Castle Biosciences has a robust research and development program, with a team of scientists and bioinformaticians working to identify new biomarkers and diagnostic tests for other types of cancer. The company is committed to advancing precision medicine by integrating genomic tools into clinical practice and providing patients with individualized treatment options based on their genetic profile.

The company has been recognized for its innovative work in cancer diagnostics, receiving the 2020 Clinical Diagnostics Company of the Year award from Frost & Sullivan. Castle Biosciences also recently went public in 2019 and is traded on the NASDAQ under the ticker eCSTLe.

Overall, Castle Biosciences Inc is a leading medical technology company that is helping to advance the field of precision medicine by developing highly accurate and clinically actionable diagnostics for challenging cancer types.


   Company Address: 505 S. Friendswood Drive Friendswood 77546 TX
   Company Phone Number: 788-9007   Stock Exchange / Ticker: NASDAQ CSTL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Castle Biosciences Inc

Castle Biosciences Inc reports $0.04 million tax charge in Q4 financial results

Castle Biosciences Inc is a medical laboratory company that specializes in providing diagnostic tests and services for the detection and monitoring of various diseases. The company recently reported its financial performance for the October to December 2023 period, revealing positive results and strong growth.
During this period, Castle Biosciences Inc saw a significant improvement in its earnings per share (EPS), with a decrease in loss per share from $-0.76 to $-0.09 compared to the same period the previous year. This improvement in EPS was also evident when comparing to the previous quarter's loss per share of $-0.26. These positive results indicate that the company has been able to reduce its losses and move closer to profitability.

Castle Biosciences Inc

Castle Biosciences Inc Reports Increased Loss per Share, But Strong Revenue Growth in Q1 2023

Castle Biosciences Inc has released its latest financial report for the first quarter of the 2023 earnings season, revealing an increase in its loss per share. The company recorded a loss of $-1.10 per share, which is significantly higher than the $-0.47 loss per share it reported in the same quarter the previous year. Additionally, the company's loss from the previous quarter surged from $-0.76 per share.
However, it was not all bad news for Castle Biosciences Inc. The company reported a strong revenue growth of 79.071%, with revenue increasing to $42.04 million from $23.48 million in the corresponding quarter a year before. Unfortunately, revenue tumbled sequentially by -34.27%, dropping from $63.95 million.






 

Castle Biosciences Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Castle Biosciences Inc does not provide revenue guidance.

Earnings Outlook
Castle Biosciences Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com